<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765946</url>
  </required_header>
  <id_info>
    <org_study_id>MetAge</org_study_id>
    <nct_id>NCT01765946</nct_id>
  </id_info>
  <brief_title>Metformin and Longevity Genes in Prediabetes</brief_title>
  <official_title>Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-diabetes, a condition characterized by hyperglycaemia, is associated with increased&#xD;
      cardiovascular risk and reduced life expectancy, as compared to the general population.&#xD;
      AMP-activated protein kinase (AMPK) is an enzyme that plays a key role in cellular energy&#xD;
      homeostasis and metabolism, and recently it has been demonstrated that AMPK regulates aging&#xD;
      pathways, as well. AMPK is susceptible to modulation through pharmacologic (e.g. metformin)&#xD;
      and non-pharmacologic (e.g. physical exercise) interventions. This clinical trial aims to&#xD;
      describe the effects of the AMPK pathway on longevity genes and inflammation in the setting&#xD;
      of pre-diabetes in vivo and in vitro. To this end, the investigators will compare treatment&#xD;
      with metformin (500 mg t.i.d) for 2 months, versus placebo in pre-diabetic subjects. The&#xD;
      investigators will assess expression of longevity genes SIRT1, p66Shc, p53 and mTOR in&#xD;
      peripheral blood mononuclear cells (PBMCs) ex vivo. The investigators will evaluate monocyte&#xD;
      polarization by flow cytometry, according to the expression of surface antigens (CD68, CCR2,&#xD;
      CD163, CD206, CX3CR1) to determine the prevalence of pro- or anti-inflammatory cells.&#xD;
      Inflammatory cytokines (TNF-alpha, MCP-1, IL-1, IL-6, IL-10, CCL12) will also be determined.&#xD;
      In the in vitro study the investigators will evaluate the effects of AMPK activation or&#xD;
      inhibition on longevity gene and protein expression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Longevity gene expression</measure>
    <time_frame>2 month after treatment</time_frame>
    <description>Change in the expression of longevity genes Sirtuin-1, p66Shc, mTor, p53 in peripheral blood mononuclear cells (PBMC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>2 months after treatment</time_frame>
    <description>A dynamic measure of insulin sensitivity (Si) from the frequently sampled OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte polarization status</measure>
    <time_frame>2 months after treatment</time_frame>
    <description>Polarization of circulating monocytes in M1 (CD68+CCR2+) and M2 (CX3CR1+CD163+/CD206+)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Prediabetes</condition>
  <condition>Aging</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin tablets 500 mg tid for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tables tid for 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin tablets 500 mg tris in die (tid)</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pre-diabetes, defined as IFG (fasting glucose between 100 and 125 mg/dl) or IGT (2h&#xD;
             post-oral glucose load (75g) between 140 and 199 mg/dl);&#xD;
&#xD;
          -  Age 40-75 years;&#xD;
&#xD;
          -  Both genders.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 or 2 diabetes mellitus;&#xD;
&#xD;
          -  Pregnancy, lactation;&#xD;
&#xD;
          -  Acute, chronic or inflammatory diseases;&#xD;
&#xD;
          -  Neoplasms;&#xD;
&#xD;
          -  Immunological diseases, organ transplantation, steroid therapy;&#xD;
&#xD;
          -  Uncontrolled arterial hypertension (systolic pressure &gt; 180 mmHg or diastolic &gt; 120&#xD;
             mmHg);&#xD;
&#xD;
          -  Recent(within 3 months) surgical intervention or cardiovascular accidents;&#xD;
&#xD;
          -  Known allergy to metformin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelo Avogaro, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Padova</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Diabetes Outpatient Clinic</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>January 8, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <last_update_submitted>March 12, 2013</last_update_submitted>
  <last_update_submitted_qc>March 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Padova</investigator_affiliation>
    <investigator_full_name>Angelo Avogaro</investigator_full_name>
    <investigator_title>Full professor of Endocrinology and Metabolism</investigator_title>
  </responsible_party>
  <keyword>Insulin resistance</keyword>
  <keyword>Prediabetes</keyword>
  <keyword>Longevity genes</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

